Zeus Archives - Medical Design Sourcing

Zeus opens Minnesota catheter manufacturing facility

A rendering of the new Zeus facility in Arden Hills, Minnesota [Image courtesy of Zeus]

Zeus has opened its catheter manufacturing facility in Arden Hills, Minnesota, celebrating the new facility with a grand opening today.

The 75,600-ft² building is home to CathX Medical, which Zeus acquired 2021. The facility has advanced R&D lab and cleanroom space for designing, developing and validating medical catheter prototypes. The facility’s capabilities include laser cutting, ablation, and welding.

Zeus said the facility will have more than 100 employees.

“Establishing a presence in Minnesota will create opportunities for innovation and partnership with our current OEM and medical device customers. It will also open doors for new relationships,” Zeus President and CEO Steve Peterson said in a news release. “As we continue expanding globally, we are honored to now be part of this medically …

Zeus Industrial Products founder passes away

Frank Paul Tourville Sr. — who founded Zeus 54 years ago and built it into a major provider of advanced medical tubing products — recently passed away at age 87.

The Orangeburg, S.C.–based company in its announcement of Tourville’s March 16 death described him as a well-known and highly regarded visionary in the polymer extrusion industry.

Get the full story on our sister site Medical Tubing + Extrusion.

DTW Podcast: Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently

Medtronic CEO Geoff Martha and Ajax CEO Duke Rohlen share insights and wisdom on this episode of the podcast.

Less than a year into his role as CEO, Geoff Martha and the Medtronic leadership has overseen a significant reorganization of medtech’s largest player.

In our closing keynote conversation, Martha says the company is clearing a minor COVID-19 bump and sees open road for the company to continue to grab share from competitors.

Martha details what products are gaining the most traction while also identifying those that still have some ground to gain.

We also discuss: When it may bring its renal denervation project to the FDA Why Hugo the surgical robot will be worth the wait (and why development has taken more than a decade) Whether or not Medtronic will collaborate more with private equity firms, early-stage incubators and maybe even SPACs? What will the company’s acquisition strategy look like in 2021. And why. Why the price-cutting for drug-eluting …